Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

Thomas E. Witzig, Arturo Molina, Leo I. Gordon, Christos Emmanouilides, Russell J. Schilder, Ian W. Flinn, Mohamed Darif, Roger Macklis, Katie Vo, Gregory A. Wiseman

Research output: Contribution to journalArticle

146 Scopus citations

Abstract

BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS. A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.

Original languageEnglish (US)
Pages (from-to)1804-1810
Number of pages7
JournalCancer
Volume109
Issue number9
DOIs
StatePublished - May 1 2007

Keywords

  • Non-Hodgkin lymphoma (NHL)
  • Radioimmunotherapy
  • Time to progression (TTP)
  • Y ibritumomab tiuxetan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan'. Together they form a unique fingerprint.

  • Cite this

    Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J., Flinn, I. W., Darif, M., Macklis, R., Vo, K., & Wiseman, G. A. (2007). Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 109(9), 1804-1810. https://doi.org/10.1002/cncr.22617